A major theme of this year’s AACR meeting examines the approaches that aim...
- CD40 agonist developments could support Anti-PD-(L)1 therapy in pancreatic cancer
- ILC 2018: Allergan’s cenicriviroc shows continued fibrosis response in NASH patients in two year extended study
- Public-private partnerships continue to play a critical role in influenza vaccine R&D
- Pain takes largest share of clinical trials in 2017
- Status of immuno-oncology clinical trials, 2008–2017
CD40 agonist developments could support Anti-PD-(L)1 therapy in pancreatic cancer
A major theme of this year’s AACR meeting examines the approaches that aim to further improve the anti-tumour efficacy of anti-PD-1 and –PD-L1 checkpoint inhibitors (CPIs) in the clinic.
ILC 2018: Madrigal Therapeutics’ MCL-3196 reduces liver fat in NASH patients
Clinical efficacy data for Madrigal Therapeutics’ Phase II NASH therapeutic, MCL-3196, which was presented at the 2018 International Liver Congress (ILC) in Paris, France, demonstrated the investigational drug met its primary endpoint of liver fat reduction versus a placebo.
ILC 2018: Allergan’s cenicriviroc shows continued fibrosis response in NASH patients in two year extended study
Evidence that Allergan’s Phase III drug candidate, cenicriviroc, may benefit non-alcoholic steatohepatitis (NASH) patients was presented at the 2018 International Liver Congress (ILC) in Paris, France.
Deals this week: Intec Pharma, FIMECS, Mereo Biopharma Group
Israeli drug development company Intec Pharma Ltd has issued an underwritten public offering of shares of its common stock.
Deals this week: Biohaven, Cellectis, Antisense Therapeutics
US-based biopharmaceutical company Biohaven Pharmaceutical Holding Company Ltd has opted to issue two million shares of its common stock in a public offering.
Hizentra for the Treatment of Patients with CIDP
Hizentra® (immune globulin subcutaneous 20% liquid) is a subcutaneous infusion indicated for the treatment of patients with chronic inflammatory demyelinating polyneuropathy (CIDP).
Eligen® Technology Mechanism of Action
Emisphere's Eligen® Technology binds a delivery agent with a therapeutic compound without alternation. This process occurs when both agent and compound are in close proximity.
B&W Tek NanoRam Handheld Raman Spectrometer
The NanoRam is a state-of-the-art handheld Ramen instrument for non-destructive identification and verification of incoming raw materials such as active pharmaceutical ingredients (API), excipients, and intermediates.
Steglatro (ertugliflozin) for the Treatment of Type 2 Diabetes
Steglatro™ (ertugliflozin) is a combination drug indicated for the improvement of glycaemic control in adult patients with Type 2 diabetes mellitus.
Read our magazine
Pharma Technology Focus is the essential reading material for decision-makers in the pharmaceutical industry, bringing you the latest news and analysis in an exciting, interactive format.